New drug combo trial offers hope for advanced stomach cancer patients
NCT ID NCT07362186
Summary
This study is testing whether a new drug combination (LM-108 plus toripalimab) works better than standard chemotherapy (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The trial will enroll 400 participants whose tumors test positive for a specific marker called CCR8. Researchers will compare how long patients live and how well the cancer is controlled between the two treatment groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC GC AND GCJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.